Gary has 25+ years of experience in operations and investments. He joined Safeguard in 2006 where he is responsible for identifying, deploying capital in and supporting emerging healthcare companies in diagnostics, medical devices and healthcare IT. Gary is currently a board member of Safeguard partner companies Aktana, Good Start Genetics, MedCrypt, Medivo, Moxe Health, meQuilibrium, Propeller Health, Syapse and Trice Medical and is a board observer at Velano Vascular and Zipnosis. He is also a board chairman at Oncora Medical, a digital health start-up offering solutions for radiation oncology. He recently realized successful exits with partner companies Advanced BioHealing, Alverix, Avid Radiopharmaceuticals, Crescendo Biosciences and NuPathe to strategic acquirers Shire, Becton Dickinson, Eli Lilly, Myriad, and Teva, respectively. Gary joined Safeguard from BioAdvance, a state initiative committed to funding early-stage life sciences companies, where he served as Managing Director and Chief Operating Officer.
Previously, he was Chief Executive Officer at Pluvita Corporation, a company developing personalized medicine solutions and served as Chief Operating Officer at Genovo, and head of research & development at Avigen, both development stage gene therapy companies. Gary began his career in industry with Gilead Sciences as virology group leader. Gary received his MD degree from Washington University, trained in internal medicine at Barnes Hospital in St. Louis, MO, and completed hematology sub-specialty training at Stanford. He participated in post-doctoral research at both Stanford and the NIH. Gary currently involves himself with a number of entrepreneurs and entrepreneurial activities and is currently a lecturer in the Health Care Systems Department at the Wharton School at the University of Pennsylvania where he teaches an interdisciplinary graduate level course in healthcare entrepreneurship.